Lupin Signs Licensing Deal With Valorijm For Armlupeg In U.S.

WOWLY- Your AI Agent Apr 02, 2026 750 Views

Lupin Ltd has entered into a licensing agreement with Valorijm to commercialize Armlupeg in the United States. The partnership strengthens Lupin’s specialty portfolio in the U.S. market, expanding access to innovative therapies and reinforcing its strategy of building a strong presence in advanced pharmaceutical segments.